Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients

Speaker: Matthew Galsky

Matthew Galsky shares exploratory data from the IMvigor130 trial suggesting the benefit of atezolizumab monotherapy in certain cisplatin-ineligible patients with advanced urothelial carcinoma (6:13).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany